Repurposing Drugs: Lessons from Rheumatology in the COVID-19 Pandemic

被引:1
作者
Manoj, Manesh [1 ]
Bafna, Prashant [1 ]
Sahoo, Rasmi Ranjan [1 ]
Hazarika, Kasturi [1 ]
Wakhlu, Anupam [1 ]
机构
[1] King Georges Med Univ, Dept Clin Immunol & Rheumatol, Lucknow 226003, Uttar Pradesh, India
关键词
Artificial intelligence; bacillus Calmette-Guerin; cytokine storm; drug repositioning; drug repurposing; vaccinology; INFLAMMATION; MECHANISMS; INJURY;
D O I
10.4103/injr.injr_323_20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Humanity currently faces one of its biggest challenges, created by a tiny quasi-life form, the severe acute respiratory syndrome coronavirus 2. The rapidity of spread and the enormous burden placed on public health infrastructure by the coronavirus disease 2019 (COVID-19) pandemic has forced researchers to look for quick answers for therapy. Drug repurposing is probably the quickest way to develop an effective therapy in a very short time. With additional input from artificial intelligence (AI), drug repurposing may emerge as one of the major techniques by which humanity can overcome this as well as future challenges. The field of rheumatology has been one of the biggest benefactors of drug repurposing. This article reviews the various ways drugs used in rheumatological disorders are being repurposed for possible COVID-19 treatment. An overview of other nonantiviral drugs being repurposed is also undertaken, and the role of AI in drug repurposing is touched upon.
引用
收藏
页码:179 / 186
页数:8
相关论文
共 50 条
  • [21] A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics
    Wattanakul, Thanaporn
    Chotsiri, Palang
    Scandale, Ivan
    Hoglund, Richard M.
    Tarning, Joel
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (08) : 945 - 958
  • [22] Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight
    Akilesh, Sai M.
    Rajesh, J.
    Palanisamy, Dhanabal
    Wadhwani, Ashish
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2021, 22 (02) : 192 - 199
  • [23] The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience
    Gozzo, Lucia
    Longo, Laura
    Vitale, Daniela Cristina
    Drago, Filippo
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [24] Cardiac Registries During the COVID-19 Pandemic: Lessons Learned
    Singh, Jyotpal
    Durr, Michael-Roy R.
    Deptuch, Elena
    Sultana, Sabiha
    Mehta, Neha
    Garcia, Santiago
    Henry, Timothy D.
    Dehghani, Payam
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (06) : 659 - 665
  • [25] Imaging in the COVID-19 era: Lessons learned during a pandemic
    Sideris, Georgios Antonios
    Nikolakea, Melina
    Karanikola, Aikaterini-Eleftheria
    Konstantinopoulou, Sofia
    Giannis, Dimitrios
    Modahl, Lucy
    WORLD JOURNAL OF RADIOLOGY, 2021, 13 (06): : 192 - 222
  • [26] Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19
    Norinder, Ulf
    Tuck, Astrud
    Norgren, Kalle
    Kos, Vesna Munic
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 130
  • [27] Co-Management of COVID-19 and Heart Failure During the COVID-19 Pandemic: Lessons Learned
    Palazzuoli, Alberto
    Lavie, Carl J.
    Severino, Paolo
    Dastidar, Amardeep
    Sammut, Eva
    McCullough, Peter A.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (06)
  • [28] Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps
    Ino, Hiroyasu
    Nakazawa, Eisuke
    Akabayashi, Akira
    CAMBRIDGE QUARTERLY OF HEALTHCARE ETHICS, 2021, 30 (01) : 51 - 58
  • [29] Drug Repurposing in the Treatment of COVID-19
    Soylu, Mehmet
    Ozbek, Emine Nur
    Yetik Anacak, Gunay
    BEZMIALEM SCIENCE, 2020, 8 : 84 - 93
  • [30] Data deprivations, data gaps and digital divides: Lessons from the COVID-19 pandemic
    Naude, Wim
    Vinuesa, Ricardo
    BIG DATA & SOCIETY, 2021, 8 (02):